At BetterLife Pharma Inc., our mission is delivering a better life.
BetterLife is an emerging biotechnology company primarily focused on developing and commercializing two compounds, TD-0148A and TD-010, to treat neurological disorders such as depression, cluster headaches and anxiety.
TD-0148A is being developed for the treatment of major depressive disorder. It has been synthesized using BetterLife’s patented manufacturing process and is the only non-hallucinogenic and non-controlled psychedelic candidate on the market. It is unique in that it is not regulated and therefore can be self-administered. TD-010 is a treatment of anxiety without the addictive potential of benzodiazepines. TD-0148A and TD-010 are both in Preclinical and IND-enabling studies.
The global depression drugs market reached US$12.41 billion in 2019 and it is projected to reach near US$25 billion by 2030. According to the WHO, depression is one of the leading causes of disability, impacting approximately 265 million people in the world.
For further information please visit www.abetterlifepharma.com
Ahmad Doroudian, PhD, Chief Executive Officer & Director
20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, Integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®
Hooshmand Sheshbaradaran, PhD, Chief Operating Officer
30+ years senior pharma executive with experience in global drug development, marketing, business strategy, operations, licensing and M&A
Senior executive roles at Pharmacia/Pfizer, Roche, Zeneus/Cephalon, Niiki Pharma, Psioxus
Development of Camptosar®, Ellence®, Emcyt®, Sutent® and Vidaza®.
Moira Ong, CPA, CA, Chief Financial Officer
18+ years’ experience as VP of Finance & CFO in several private and public companies including Merus Labs (NASDAQ: MSLI), BetterLife Pharma (CNSX: BETR; formerly Pivot Pharmaceuticals)
Managed the integration of the supply chain management and accounting Vancocin, Enablex®/Emselex®, acquired from Novartis, by Merus Labs International Inc.
Previously at Grant Thornton and Deloitte
Jeff Fellows, Head of Regulatory
30+ years of drug development experience leading regulatory development efforts
Worked with early stage development companies and a large multinational biopharmaceutical enterprise developing programs across numerous therapeutic areas
Previously VP of Regulatory Affairs at Cell Therapeutics (currently CTI BioPharma, NASDAQ and MTA: CTIC), held senior positions in Regulatory Affairs at Amgen
Scott Rudge, PhD, Head of CMC
Founded CMC development expert services group in 2004, has worked on over 200 projects for all molecule/therapy classes since
Site Director & VP Operations for FeRx; increasing management responsibility at NIST, Synergen, Amylin
PhD in Chemical Engineering from Purdue and author of multiple peer reviewed articles